Drug Trial Radar · NCT05943886
A Phase 1 Study of HEC88473 Injection in Healthy Subjects, Obese Subjects and T2DM Subjects
Last checked: Nov 19, 2026Latest source record: Jul 17, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
164
Actual
Start
Aug 11, 2021
Primary completion
Feb 17, 2023
Study completion Feb 17, 2023
Sponsor
- Lead sponsor
- Dongguan HEC Biopharmaceutical R&D Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Jul 13, 2023
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Sequential
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years, up to 65 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
This is a single-center, randomized, double-blind, placebo-controlled, escalating single-dose and multiple-dose study to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of HEC88473 injection in healthy subjects, obese subjects and subjects with type 2 diabetes mellitus (T2DM).
Conditions
- Healthy Subjects
- Obesity
- T2DM (Type 2 Diabetes Mellitus)
Interventions
HEC88473 injectionDrug
HEC88473 will be provided as a 17 mg/mL solution and will be administered by subcutaneous injection in the abdomen.
PlaceboDrug
Placebo will be administered by subcutaneous injection in the abdomen.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) after a single dose of HEC88473Time frame: Baseline to day 15
- Frequency and severity of Adverse Events (AEs) and Serious Adverse Events (SAEs) after multiple dose of HEC88473Time frame: Baseline to day 43
- CmaxTime frame: Predose and postdose 4、8、10、12、14、24、48、72、96、168、216、336 hours
- AUCTime frame: Predose and postdose 4、8、10、12、14、24、48、72、96、168、216、336 hours
Locations
1 site in 1 country. Site status is shown where the registry gives one.
The First Hospital of Jilin University
Changchun, Jilin, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.